Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term B cell. Found 6 abstracts

Fang P, Li X, Dai J, Cole L, Camacho JA, Zhang Y, Ji Y, Wang J, Yang XF, Wang H. Immune cell subset differentiation and tissue inflammation. Journal of hematology & oncology. 2018 Jul 31;11(1):97.   PMCID: PMC6069866
Gitelson E, Al-Saleem T, Robu V, Millenson MM, Smith MR. Pediatric nodal marginal zone lymphoma may develop in the adult population. Leukemia & lymphoma. 2010 Jan;51(1):89-94.   PMCID: not NIH funded
Rowley B, Tang L, Shinton S, Hayakawa K, Hardy RR. Autoreactive B-1 B cells: Constraints on natural autoantibody B cell antigen receptors. Journal of Autoimmunity. 2007 Jan;29(4):236-45.
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
Wen L, Shinton SA, Hardy RR, Hayakawa K. Association of B-1 B Cells with Follicular Dendritic Cells in Spleen. Journal of Immunology. 2005 Jan;174(11):6918-26.
Chang Y, Bosma MJ, Bosma GC. Extended duration of DH-JH rearrangement in immunoglobulin heavy chain transgenic mice: Implications for regulation of allelic exclusion. Journal of Experimental Medicine. 1999 Apr 19;189(8):1295-305.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term B cell

B cell differentiation and 39 months post achievement of complete remission One patient died Dendritic cell (Follicular pre-b severe comorbidities or who refused treatment with radiation lesions presentations of CBCL ig-beta adult rituximab Cell differentiation lymphoid malignancies germinal-centers variant Lymphocyte (plasma cell light-chain if m(2) Maintenance therapy Spleen (assocn of B-1 B cells with follicular dendritic cells in spleen) lymphoma Dendritic cell SYSTEMIC THERAPY m(2) once every 2-3 months Objective PATTERN Monocyte FOLLICULAR-GROWTH DENDRITIC CELLS either primary CBCL or low-grade effective in treating of CBCL Aging Spleen (autoreactive B-1 B cells and natural autoantibody B cell antigen receptors) Macrophage ELDERLY-PATIENTS contraindicated or unwanted Additional collaborative studies are autoreactive B-1 B cells and natural autoantibody B cell antigen receptors) broken dna-molecules remission One patient received local radiotherapy to a solitary immunoglobulin transgenic mice v(d)j recombination unclassified) Phosphatidylcholines Role: BSU (Biological study-BIOL (Biological study) (assocn of B-1 B cells with follicular dendritic cells in spleen) lymphomas with relapses limited to the skin Rituximab appears to Lymphoma b-cell lymphoma Cardiovascular disease deficiency each with either extensive established We treated five patients with rituximab given as a single agent for four weekly therapy combined immune- 19 ongoing complete clinical remissions with a median follow-up of 17 mouse bone-marrow remission from the low-grade CBCL present an attractive alternative when radiation therapy is CYTOTOXIC T-CELLS CD5 clinical presentation Immune cell subset differentiation ANTI-CD20 MONOCLONAL-ANTIBODY Cancer EORTC CLASSIFICATION allelic exclusion assocn of B-1 B cells with follicular dendritic cells in spleen) was given at 375 mg initiated lineage cells Peritoneum (cavity T cell clinical responses occurred in all five patients Three patients have Bone marrow no recurrences of either grade CBCL b-cell development have yet occurred Treatment was well tolerated Rituximab is safe and BCR unclassified) Phosphatidylcholines Role: BSU (Biological study-BIOL (Biological study) (autoreactive B-1 B cells and natural autoantibody B cell antigen receptors) lymphocyte dendritic cell spleen CXCR5 CD5 antigen unclassified) Antibodies and Immunoglobulins Role: BSU (Biological study-BIOL (Biological study) (autoantibodies progressive transformation TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be unclassified) Antibodies and Immunoglobulins Role: BSU (Biological study-BIOL (Biological study) (IgM marginal zone lymphoma at age 87 years from a non-related cause after 55 years of complete scid mice B cell receptor IgM autoantibody VH Vkappa V(D)J rearrangement follicular lymphoma cutaneous CHOP CHEMOTHERAPY intravenous infusions of 375 mg hodgkins-disease cutaneous site of large-cell lymphoma that developed after 3 years in pediatric malignancy unclassified) Chemokine receptors Role: BSU (Biological study-BIOL (Biological study) (CXCR5 NON-HODGKINS-LYMPHOMA Newborn needed to assess the role of rituximab in various clinicopathologic
Last updated on Wednesday, February 05, 2020